A review of phytocannabinoids and endocannabinoids found diverse pharmacological activities relevant to CNS diseases including epilepsy, pain, neurodegeneration, and psychiatric disorders, though clinical evidence varies widely by condition.
Neurologists, neuroscience researchers, and clinicians interested in cannabinoid therapeutics for brain disorders.
Cannabinoid pharmacology spans epilepsy, pain, neurodegeneration, and psychiatric disorders
What the researchers found
Both plant-derived (phyto) and endogenous cannabinoids show pharmacological activities relevant to multiple CNS conditions. Evidence quality ranges from well-supported (epilepsy) to preliminary (neurodegeneration, psychiatric disorders).
Why it matters
The endocannabinoid system is active throughout the brain and involved in nearly every neurological function. Understanding how both external and internal cannabinoids modulate brain disease opens numerous therapeutic avenues.
The numbers in context
Review covers phytocannabinoids (THC, CBD, others) and endocannabinoids (anandamide, 2-AG) across multiple CNS disease categories.
How the study worked
Literature review using keyword searches across databases focusing on cannabinoid pharmacology and CNS disease applications. Covers both phytocannabinoids and endocannabinoids.
What this study cannot tell us
Narrative review without systematic methodology. Covers a very broad topic with variable evidence depth. Much of the evidence is preclinical. Does not provide quantitative evidence synthesis.
How to read the evidence
Broad narrative review. Useful overview but limited by scope breadth and lack of systematic evidence grading.
When this study was published
Published 2023.
The bigger picture
The diversity of CNS conditions potentially influenced by cannabinoid signaling reflects the central role of the endocannabinoid system in brain function. Translating this broad pharmacology into targeted therapies remains the key challenge.
Questions still open
- Which CNS conditions have the strongest clinical evidence for cannabinoid-based therapies beyond epilepsy? How can the broad pharmacology of cannabinoids be harnessed for specific conditions without off-target effects?
Common questions
Can cannabinoids treat brain diseases?
What is the difference between phytocannabinoids and endocannabinoids?
Read the original research
The impact of phyto- and endo-cannabinoids on central nervous system diseases：A review.
Journal of traditional and complementary medicine, 13(1), 30-38
Citation
Zhang, Shan-Shan; Zhang, Niu-Niu; Guo, Tian-Tian; Sheen, Lee-Yan; Ho, Chi-Tang; Bai, Nai-Sheng. (2023). The impact of phyto- and endo-cannabinoids on central nervous system diseases：A review.. Journal of traditional and complementary medicine, 13(1), 30-38. https://doi.org/10.1016/j.jtcme.2022.10.004
Explore the wider topic
- CBD Oil Quality Guide: How to Avoid Snake Oil
- Anxiety After Quitting Weed: When to Consider Medication
- Cannabis for Chemotherapy Nausea: What the Evidence Actually Shows
- Cannabis for Chronic Pain: What the Research Actually Supports
- Cannabis and Epilepsy: The Epidiolex Story and What It Means
- Does CBD Actually Work for Anxiety? What the Evidence Shows
- Does CBD Help with Weed Withdrawal? What Studies Show
- CBD vs THC: The Differences That Actually Matter
- The Proven Medical Benefits of Cannabis: What Research Supports
- Quitting Weed Before Surgery
- Weed and Medications: What Changes When You Quit
- Quitting Weed During Pregnancy: What You Need to Know
- Quitting Weed While Pregnant: What You Need to Know
- Cannabis and Older Adults: Risks Seniors Should Know
- Cannabis and Breastfeeding: THC in Breast Milk